Razelle Kurzrock
University of California, San Diego
PharmacokineticsCancerInternal medicineSurgeryPathologyOncologyAdverse effectImmunologyChronic myelogenous leukemiaTargeted therapyIn patientCancer researchClinical trialBioinformaticsMedicineBiologyGastroenterologyPharmacology
1,279Publications
137H-index
48.6kCitations
Publications 1,292
Newest
#1Shumei Kato (UCSD: University of California, San Diego)H-Index: 26
Last. Razelle KurzrockH-Index: 137
view all 8 authors...
PURPOSECancer of unknown primary (CUP) is a metastatic disease with unidentifiable primary tumor. Somatic alterations can be assessed noninvasively via liquid biopsies interrogating cell-free DNA (...
Source
#1Jaren Mullen (UCSD: University of California, San Diego)
#2Shumei Kato (UCSD: University of California, San Diego)H-Index: 26
Last. Razelle KurzrockH-Index: 137
view all 4 authors...
Abstract null null Genes encoding SWI/SNF chromatin remodeling complex subunits are collectively mutated in approximately 20% of human cancers. ARID1A is a SWI/SNF subunit gene whose protein product binds DNA. ARID1A gene alterations result in loss of function. It is the most commonly mutated member of the SWI/SNF complex, being aberrant in ∼6% of cancers overall, including ovarian clear cell cancers (∼45% of patients) and uterine endometrioid cancers (∼37%). ARID1A has a crucial role in regulat...
Source
#1Sylvia AdamsH-Index: 52
#2Megan Othus (Fred Hutchinson Cancer Research Center)H-Index: 29
Last. Razelle KurzrockH-Index: 137
view all 28 authors...
Purpose null Metaplastic breast cancer (MpBC) is a rare aggressive subtype that responds poorly to cytotoxics. Median survival is approximately eight months for metastatic disease. We report results for advanced MpBC treated with ipilimumab+nivolumab, a cohort of S1609 for rare cancers (DART: NCT02834013). null Methods null Prospective, open-label, multicenter phase II (two-stage) trial of ipilimumab (1mg/kg IV q6weeks) plus nivolumab (240mg IV q2weeks) for advanced MpBC. Primary endpoint was ob...
Source
Abstract null Background null Methods that enable monitoring of therapeutic efficacy of autologous chimeric antigen receptor (CAR) T-cell therapy will be clinically useful. null Objectives null The aim of this study is to demonstrate the feasibility of blood-derived cell-free DNA (cfDNA) to predict CAR T-cell therapy response in patients with refractory B-cell lymphomas. null Study design null Whole blood was collected prior to and throughout CAR T-cell therapy until day +154. Low-coverage (∼0.4...
Source
#1Timothy V. Pham (UCSD: University of California, San Diego)H-Index: 4
#2Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 21
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 137
view all 5 authors...
Background null Tumor mutational burden (TMB) may be a predictive biomarker of immune checkpoint inhibitor (ICI) responsiveness. Genomic landscape heterogeneity is a well-established cancer feature. Molecular characteristics may differ even within the same tumor specimen and undoubtedly evolve with time. However, the degree to which TMB differs between tumor biopsies within the same patient has not been established. null Methods null We curated data on 202 patients enrolled in the PREDICT study ...
Source
#1Kristina Mardinian (UCSD: University of California, San Diego)H-Index: 1
#2Jacob J. Adashek (USF: University of South Florida)H-Index: 12
Last. Razelle KurzrockH-Index: 137
view all 5 authors...
The SWI/SNF chromatin remodeling complex, via nucleosome topology modulation, regulates transcription. The SMARCA4 (BRG1) subunit codes for the ATPase energy engine of the SWI/SNF complex. SMARCA4 is a tumor suppressor that is aberrant in ∼5% to 7% of human malignancies. Class I SMARCA4 alterations (truncating mutations, fusions, and homozygous deletion) lead to loss of function whereas class II alterations (missense mutations) have a dominant negative/gain-of-function effect and/or loss-of func...
Source
BACKGROUND Malignancies are molecularly complex and become more resistant with each line of therapy. We hypothesized that offering matched, individualized combination therapies to patients with treatment-naive, advanced cancers would be feasible and efficacious. Patients with newly diagnosed unresectable/metastatic, poor-prognosis cancers were enrolled in a cross-institutional prospective study. METHODS A total of 145 patients were included in the study. Genomic profiling (tissue and/or circulat...
Source
#1Gregory P. Botta (UCSD: University of California, San Diego)H-Index: 7
#2Shumei Kato (UCSD: University of California, San Diego)H-Index: 26
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 137
view all 7 authors...
Background null Immune checkpoint inhibitors (ICIs), which have transformed the care of multiple malignancies, fail to demonstrate efficacy in pancreatic cancer. Recently, genomic biomarkers have been associated with response to ICIs: microsatellite instability high (MSI-H) and tumor mutation burden (TMB) ≥10 mutations/Mb. Some investigations suggest that alterations in Switch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling genes may predispose to improved outcomes with immunotherapy. The...
Source
#1Sandip Pravin Patel (UCSD: University of California, San Diego)H-Index: 29
#2Edward Mayerson (Fred Hutchinson Cancer Research Center)H-Index: 5
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 137
view all 15 authors...
BACKGROUND The authors previously reported the results of the nonpancreatic neuroendocrine neoplasm cohort of the SWOG S1609 DART (Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors) trial, which permitted all histologic grades and had a 44% overall response rate (ORR) among patients with high-grade disease. Here they sought to validate their findings in a dedicated prospective cohort of high-grade neuroendocrine neoplasms within S1609. METHODS A prospective, open-label, multicenter, phase 2...
Source
#1Milind Javle (University of Texas MD Anderson Cancer Center)H-Index: 49
#2Mitesh J. Borad (Mayo Clinic)H-Index: 46
Last. Christopher Sweeney (Harvard University)H-Index: 80
view all 19 authors...
Summary null null Background null Systemic therapies for metastatic biliary tract cancers are few, and patients have a median overall survival of less than 1 year. MyPathway evaluates the activity of US Food and Drug Administration-approved therapies in non-indicated tumours with potentially actionable molecular alterations. In this study, we present an analysis of patients with metastatic biliary tract cancers with HER2 amplification, overexpression, or both treated with a dual anti-HER2 regime...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.